Buy Mankind Pharma: IIFL Securities's Target Price Rs 2325

IIFL Securities has recommended buying Mankind Pharma at the current market price of Rs 2244.25, with a target price of Rs 2325. The brokerage is bullish on the stock due to its strong brand portfolio, growing market share, and expansion into new segments. Mankind Pharma is one of the leading pharmaceutical companies in India with a presence in over 20 countries. The company's product portfolio includes over 500 brands across various therapeutic areas, including dermatology, anti-infectives, respiratory, gastrointestinal, and vitamins.

About Mankind Pharma:

Mankind Pharma is an Indian multinational pharmaceutical company headquartered in New Delhi, India. It was founded in 1995 by Rajeev Juneja. The company manufactures and markets a wide range of pharmaceutical products, including antibiotics, anti-infectives, cardiovascular drugs, gastrointestinal drugs, and dermatological products. Mankind Pharma has a strong presence in India and has also expanded its operations to over 50 countries worldwide. The company's products are sold under various brand names, including Mankind, Unichem, and Ajanta.

52 Week Price Trend:

Mankind Pharma, a renowned Indian pharmaceutical company, is currently trading at Rs 2244.25 on the NSE. This stands moderately lower than its 52-week high price of Rs 2297.4, indicating a slight pullback from its peak value. However, the stock's performance remains impressive, with its 52-week low price of Rs 1240.75 representing a significant increase of approximately 81%. This suggests that despite the recent dip, Mankind Pharma's stock has maintained a strong upward trajectory over the past year, reflecting investor confidence in the company's long-term prospects.

Stratzy's MOST Analysis:

MANKIND has received an AAA rating from Stratzy's MOST framework, indicating that the company has low fundamental risks. This rating is based on the company's strong management, positive outlook, high safety, and favorable trend. Specifically, the company has demonstrated consistent financial performance, a well-defined growth strategy, and a commitment to risk management. This positive overall assessment suggests that MANKIND is a financially sound and well-managed company that is poised for continued success.

Fundamental and Technical information provided in this blog were last updated on 22 Mar, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.